Japan records surprise trade deficit in July as exports weaken further
Ajay Royan, a director and significant shareholder of Fractyl Health , Inc. (NASDAQ:GUTS), has recently acquired a notable amount of the company’s common stock. According to a recent SEC filing, Royan purchased 17,901 shares on March 14, 2025, at an average price of approximately $1.2837 per share. The total value of this transaction is $22,979. The purchase comes as the stock trades near its 52-week low of $1.16, down over 80% in the past year. InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $6 to $10.
This acquisition increases Royan’s direct ownership in Fractyl Health, while he also holds significant indirect interests through entities such as Mithril LP and Mithril II LP. Following this transaction, Royan’s direct holdings amount to 17,901 shares, with indirect holdings totaling over 6.4 million shares in the $62.13M market cap company. Get deeper insights into GUTS with a comprehensive InvestingPro Research Report, featuring detailed analysis of the company’s financials and growth prospects.
In other recent news, Fractyl Health reported its fourth-quarter 2024 earnings, revealing a larger-than-expected loss with an EPS of -$0.52, which fell short of analyst expectations of -$0.42. The company experienced increased research and development expenses, totaling $20.3 million, up from $10.1 million in the same quarter the previous year, contributing to a net loss of $25 million compared to $19.2 million in Q4 2023. Revenue was generated from a commercial pilot in Germany, and the company held $67.5 million in cash as of the end of December 2024. Despite financial challenges, Fractyl Health remains optimistic about its RAVITA and REJUVA platforms, with plans to achieve significant milestones in 2025. The company also announced the date for its 2025 annual meeting of stockholders, set for June 11, following the absence of a meeting in 2024. Fractyl Health’s strategic focus on innovative treatments for obesity and diabetes continues, with expectations to achieve key clinical milestones in 2025. Additionally, the company outlined its plans for stockholder proposals and nominations ahead of the meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.